link.springer.com

Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease - Annals of Surgical Oncology

  • ️Kidd, Mark
  • ️Tue Mar 09 2010

  • Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72.

    PubMed  CAS  Google Scholar 

  • Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100:1282–9.

    PubMed  Google Scholar 

  • Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

    PubMed  Google Scholar 

  • Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11:1–18.

    PubMed  CAS  Google Scholar 

  • Taupenot L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134–49.

    PubMed  CAS  Google Scholar 

  • Modlin IM, Champaneria MC, Bornschein J, Kidd M. Evolution of the diffuse neuroendocrine system—clear cells and cloudy origins. Neuroendocrinology. 2006;84:69–82.

    PubMed  CAS  Google Scholar 

  • Natori S, Huttner WB. Chromogranin B (secretogranin I) promotes sorting to the regulated secretory pathway of processing intermediates derived from a peptide hormone precursor. Proc Natl Acad Sci USA. 1996;93:4431–6.

    PubMed  CAS  Google Scholar 

  • Jain RK, Joyce PB, Gorr SU. Aggregation chaperones enhance aggregation and storage of secretory proteins in endocrine cells. J Biol Chem. 2000;275:27032–6.

    PubMed  CAS  Google Scholar 

  • Gorr SU, Jain RK, Kuehn U, Joyce PB, Cowley DJ. Comparative sorting of neuroendocrine secretory proteins: a search for common ground in a mosaic of sorting models and mechanisms. Mol Cell Endocrinol. 2001;172:1–6.

    PubMed  CAS  Google Scholar 

  • Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an “on/off” switch controlling dense-core secretory granule biogenesis. Cell. 2001;106:499–509.

    PubMed  CAS  Google Scholar 

  • Woulfe J, Deng D, Munoz D. Chromogranin A in the central nervous system of the rat: pan-neuronal expression of its mRNA and selective expression of the protein. Neuropeptides. 1999;33:285–300.

    PubMed  CAS  Google Scholar 

  • Waschek JA, Pruss RM, Siegel RE, et al. Regulation of enkephalin, VIP, and chromogranin biosynthesis in actively secreting chromaffin cells. Multiple strategies for multiple peptides. Ann N Y Acad Sci. 1987;493:308–23.

    PubMed  CAS  Google Scholar 

  • Konecki DS, Benedum UM, Gerdes HH, Huttner WB. The primary structure of human chromogranin A and pancreastatin. J Biol Chem. 1987;262:17026–30.

    PubMed  CAS  Google Scholar 

  • Benedum UM, Baeuerle PA, Konecki DS, et al. The primary structure of bovine chromogranin A: a representative of a class of acidic secretory proteins common to a variety of peptidergic cells. EMBO J. 1986;5:1495–502.

    PubMed  CAS  Google Scholar 

  • Eiden LE, Huttner WB, Mallet J, et al. A nomenclature proposal for the chromogranin/secretogranin proteins. Neuroscience. 1987;21:1019–21.

    PubMed  CAS  Google Scholar 

  • Eriksson B, Arnberg H, Oberg K, et al. Chromogranins—new sensitive markers for neuroendocrine tumors. Acta Oncol. 1989;28:325–9.

    PubMed  CAS  Google Scholar 

  • Yoo SH, You SH, Kang MK, et al. Localization of the secretory granule marker protein chromogranin B in the nucleus. Potential role in transcription control. J Biol Chem. 2002;277:16011–21.

    PubMed  CAS  Google Scholar 

  • Fischer-Colbrie R, Hagn C, Kilpatrick L, Winkler H. Chromogranin C: a third component of the acidic proteins in chromaffin granules. J Neurochem. 1986;47:318–21.

    Article  PubMed  CAS  Google Scholar 

  • Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience. 1992;49:497–528.

    PubMed  CAS  Google Scholar 

  • Tatemoto K, Efendić S, Mutt V, et al. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature. 1986;324(6096):476–8.

    PubMed  CAS  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    PubMed  CAS  Google Scholar 

  • Lewis JJ, Zdon MJ, Adrian TE, Modlin IM. Pancreastatin: a novel peptide inhibitor of parietal cell secretion. Surgery. 1988;104:1031–6.

    PubMed  CAS  Google Scholar 

  • Funakoshi A, Miyasaka K, Nakamura R, et al. Bioactivity of synthetic human pancreastatin on exocrine pancreas. Biochem Biophys Res Commun. 1988;156:1237–42.

    PubMed  CAS  Google Scholar 

  • Välimäki S, Höög A, Larsson C, Farnebo LO, Bränström R. High extracellular Ca2+ hyperpolarizes human parathyroid cells via Ca(2+)-activated K+ channels. J Biol Chem. 2003;278:49685–90.

    PubMed  Google Scholar 

  • Ronchi CL, Boschetti M, Degli Uberti EC, et al. Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf). 2007;67:512–9.

    Google Scholar 

  • Fasciotto BH, Denny JC, Greeley GH Jr, Cohn DV. Processing of chromogranin A in the parathyroid: generation of parastatin-related peptides. Peptides. 2000;21:1389–401.

    PubMed  CAS  Google Scholar 

  • Kunzmann S, Schmidt-Weber C, Zingg JM, et al. Connective tissue growth factor expression is regulated by histamine in lung fibroblasts: potential role of histamine in airway remodeling. J Allergy Clin Immunol. 2007;119:1398–407.

    PubMed  CAS  Google Scholar 

  • Hertelendy ZI, Patel DG, Knittel JJ. Pancreastatin inhibits insulin secretion in RINm5F cells through obstruction of G-protein mediated, calcium-directed exocytosis. Cell Calcium. 1996;19:125–32.

    PubMed  CAS  Google Scholar 

  • Tsolakis AV, Stridsberg M, Grimelius L, et al. Ghrelin immunoreactive cells in gastric endocrine tumors and their relation to plasma ghrelin concentration. J Clin Gastroenterol. 2008;42:381–8.

    PubMed  CAS  Google Scholar 

  • O’Connor DT, Cadman PE, Smiley C, et al. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab. 2005;90:5414–25.

    PubMed  Google Scholar 

  • Sánchez-Margalet V, González-Yanes C, Santos-Alvarez J, Najib S. Pancreastatin. Biological effects and mechanisms of action. Adv Exp Med Biol. 2000;482:247–62.

    PubMed  Google Scholar 

  • Gonzalez-Yanes C, Sanchez-Margalet V. Pancreastatin, a chromogranin A–derived peptide, inhibits leptin and enhances UCP-2 expression in isolated rat adipocytes. Cell Mol Life Sci. 2003;60:2749–56.

    PubMed  CAS  Google Scholar 

  • Mahapatra NR, Taupenot L, Courel M, Mahata SK, O’Connor DT. The trans-Golgi proteins SCLIP and SCG10 interact with chromogranin A to regulate neuroendocrine secretion. Biochemistry. 2008;47:7167–78.

    PubMed  CAS  Google Scholar 

  • Mandalà M, Brekke JF, Serck-Hanssen G, Metz-Boutigue MH, Helle KB. Chromogranin A-derived peptides: interaction with the rat posterior cerebral artery. Regul Pept. 2005;124:73–80.

    PubMed  Google Scholar 

  • Blois A, Srebro B, Mandalà M, et al. The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. Regul Pept. 2006;135:78–84.

    PubMed  CAS  Google Scholar 

  • Belloni D, Scabini S, Foglieni C, et al. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J. 2007;21:3052–62.

    PubMed  CAS  Google Scholar 

  • Rao RD, Mladek AC, Lamont JD, et al. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia. 2005;7:921–9.

    PubMed  CAS  Google Scholar 

  • Pieroni M, Corti A, Tota B, et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J. 2007;28:1117–27.

    PubMed  CAS  Google Scholar 

  • Dieplinger B, Gegenhuber A, Struck J, et al. Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin Chim Acta. 2009;400:91–6.

    PubMed  CAS  Google Scholar 

  • Helle KB. Regulatory peptides from chromogranin A and secretogranin II: putative modulators of cells and tissues involved in inflammatory conditions. Regul Pept. (in press).

  • Di Comite G, Rossi CM, Marinosci A, et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. J Leukoc Biol. 2009;85:81–7.

    PubMed  CAS  Google Scholar 

  • Zhao E, Zhang D, Basak A, Trudeau VL. New insights into granin-derived peptides: evolution and endocrine roles. Gen Comp Endocrinol. 2009;164:161–74.

    Google Scholar 

  • Granberg D, Stridsberg M, Seensalu R, et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1999;84:2712–7.

    PubMed  CAS  Google Scholar 

  • Fossmark R, Jianu CS, Martinsen TC, et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol. 2008;43:20–4.

    PubMed  CAS  Google Scholar 

  • Elias AN, Wilson AF, Pandian MR, Kayaleh R. Chromogranin A concentrations in plasma of physically active men after acute exercise. Clin Chem. 1992;38:2348–9.

    PubMed  CAS  Google Scholar 

  • Takiyyuddin MA, Cervenka JH, Sullivan PA, et al. Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation. 1990;81:185–95.

    PubMed  CAS  Google Scholar 

  • Larsen AI, Helle KB, Christensen M, et al. Effect of exercise training on chromogranin A and relationship to N-ANP and inflammatory cytokines in patients with chronic heart failure. Int J Cardiol. 2008;127:117–20.

    PubMed  Google Scholar 

  • Sullivan PA, Grosch C, Lawless D, O’Connor DT. Short-term strenuous exercise training: effects on blood pressure and hormonal levels in mild hypertension. Ir J Med Sci. 1992;161:666–9.

    PubMed  CAS  Google Scholar 

  • Pinkus GS, Etheridge CL, O’Connor EM. Are keratin proteins a better tumor marker than epithelial membrane antigen? A comparative immunohistochemical study of various paraffin-embedded neoplasms using monoclonal and polyclonal antibodies. Am J Clin Pathol. 1986;85:269–77.

    PubMed  CAS  Google Scholar 

  • Moattari AR, Deftos LJ, Vinik AI. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors. J Clin Endocrinol Metab. 1989;69:902–5.

    PubMed  CAS  Google Scholar 

  • Hsiao RJ, Seeger RC, Yu AL, O’Connor DT. Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest. 1990;85:1555–9.

    PubMed  CAS  Google Scholar 

  • Guignat L, Bidart JM, Nocera M, et al. Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. Br J Cancer. 2001;84:808–12.

    PubMed  CAS  Google Scholar 

  • Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumours. Br J Haematol. 1991;79(Suppl 1):74–7.

    PubMed  Google Scholar 

  • Blind E, Schmidt-Gayk H, Sinn HP, O’Connor DT, Raue F. Chromogranin A as tumor marker in medullary thyroid carcinoma. Thyroid. 1992;2:5–10.

    PubMed  CAS  Google Scholar 

  • Schürmann G, Raeth U, Wiedenmann B, Buhr H, Herfarth C. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J Surg. 1992;16:697–701.

    PubMed  Google Scholar 

  • Kälkner KM, Janson ET, Nilsson S, et al. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res. 1995;55(23 Suppl):5801s–4s.

    PubMed  Google Scholar 

  • Boomsma F, Bhaggoe UM, Man in ‘t Veld AJ, Schalekamp MA. Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. Clin Chim Acta. 1995;239:57–63.

    Google Scholar 

  • Wassberg E, Stridsberg M, Christofferson R. Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma. J Endocrinol. 1996;151:225–30.

    PubMed  CAS  Google Scholar 

  • Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8:685–90.

    PubMed  CAS  Google Scholar 

  • Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alphasubunit of glycoprotein hormones. J Clin Endocr Metab. 1997;82:2622–8.

    PubMed  CAS  Google Scholar 

  • Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol. 2001;13:55–8.

    PubMed  CAS  Google Scholar 

  • Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol. 2001;12(Suppl 2):S69–72.

    PubMed  Google Scholar 

  • Baudin E, Bidart JM, Bachelot A, et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol. 2001;12(Suppl 2):S79–82.

    PubMed  Google Scholar 

  • Stivanello M, Berruti A, Torta M, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol. 2001;12(Suppl 2):S73–7.

    PubMed  Google Scholar 

  • Massironi S, Fraquelli M, Paggi S, et al. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Dig Liver Dis. 2009;41:31–5.

    PubMed  CAS  Google Scholar 

  • Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol. 2003;177:337–41.

    PubMed  CAS  Google Scholar 

  • Cimitan M, Buonadonna A, Cannizzaro R, et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol. 2003;14:1135–41.

    PubMed  CAS  Google Scholar 

  • Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf). 2004;60:644–52.

    CAS  Google Scholar 

  • Stridsberg M, Eriksson B, Oberg K, Janson ET. A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept. 2004;117:219–27.

    PubMed  CAS  Google Scholar 

  • Zatelli MC, Torta M, Leon A, et al; Italian CromaNet Working Group. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian multicenter study. Endocr Relat Cancer. 2007;14:473–82.

    Google Scholar 

  • Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25:1967–73.

    PubMed  CAS  Google Scholar 

  • Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798–803.

    PubMed  CAS  Google Scholar 

  • Namwongprom S, Wong FC, Tateishi U, Kim EE, Boonyaprapa S. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. Ann Nucl Med. 2008;22:237–43.

    PubMed  Google Scholar 

  • Welin S, Stridsberg M, Cunningham J, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology. 2009;89:302–7.

    PubMed  CAS  Google Scholar 

  • Gussi IL, Young J, Baudin E, Bidart JM, Chanson P. Chromogranin A as serum marker of pituitary adenomas. Clin Endocrinol (Oxf). 2003;59:644–8.

    CAS  Google Scholar 

  • Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858–65.

    PubMed  CAS  Google Scholar 

  • Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82:2622–8.

    PubMed  CAS  Google Scholar 

  • Rodrigues M, Gabriel M, Heute D, et al. Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1796–802.

    PubMed  CAS  Google Scholar 

  • Panzuto F, Severi C, Cannizzaro R, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest. 2004;27:6–11.

    PubMed  CAS  Google Scholar 

  • Stridsberg M, Oberg K, Li Q, Engström U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995;144:49–59.

    PubMed  CAS  Google Scholar 

  • Nobels FR, de Herder WW, Kwekkeboom DJ, et al. Serum chromogranin A in the differential diagnosis of Cushing’s syndrome. Eur J Endocrinol. 1994;131:589–93.

    PubMed  CAS  Google Scholar 

  • Angelsen A, Syversen U, Haugen OA, et al. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate. 1997;30:1–6.

    PubMed  CAS  Google Scholar 

  • Alessandro S, Vincenzo G, Maria AG, et al. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy. Endocr Relat Cancer. 2007;14:625–32.

    PubMed  Google Scholar 

  • Sciarra A, Di Silverio F, Autran AM, et al. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma. Urol Int. 2009;82:147–51.

    PubMed  CAS  Google Scholar 

  • Sobol RE, O’Connor DT, Addison J, et al. Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med. 1986;105:698–700.

    PubMed  CAS  Google Scholar 

  • Giovanella L, Marelli M, Ceriani L, et al. Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. Int J Biol Markers. 2001;16:268–72.

    PubMed  CAS  Google Scholar 

  • Spadaro A, Ajello A, Morace C, et al. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol. 2005;11:1987–90.

    PubMed  Google Scholar 

  • Peracchi M, Gebbia C, Basilisco G, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol. 2005;152:443–8.

    PubMed  CAS  Google Scholar 

  • Malaguarnera M, Cristaldi E, Cammalleri L, et al. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Arch Gerontol Geriatr. 2009;48:213–7.

    PubMed  CAS  Google Scholar 

  • Gulubova M, Vlaykova T. Chromogranin A-, serotonin-, synaptophysin- and vascular endothelial growth factor-positive endocrine cells and the prognosis of colorectal cancer: an immunohistochemical and ultrastructural study. J Gastroenterol Hepatol. 2008;23:1574–85.

    PubMed  Google Scholar 

  • Sidhu R, Drew K, McAlindon ME, Lobo AJ, Sanders DS. Elevated serum chromogranin A in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): a shared model for pathogenesis? Inflamm Bowel Dis. 2010;16:361.

    PubMed  Google Scholar 

  • Sørhaug S, Langhammer A, Waldum HL, Hveem K, Steinshamn S. Increased serum levels of chromogranin A in male smokers with airway obstruction. Eur Respir J. 2006;28:542–8.

    PubMed  Google Scholar 

  • Hsiao RJ, Mezger MS, O’Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int. 1990;37:955–64.

    PubMed  CAS  Google Scholar 

  • Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol. 2004;150:299–303.

    PubMed  CAS  Google Scholar 

  • Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut. 1996;39:649–53.

    PubMed  CAS  Google Scholar 

  • Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther. 1999;13:145–53.

    PubMed  CAS  Google Scholar 

  • O’Connor DT. Plasma chromogranin A. Initial studies in human hypertension. Hypertension. 1985;7(3 Pt 2):I76–9.

    PubMed  Google Scholar 

  • Takiyyuddin MA, Parmer RJ, Kailasam MT, et al. Chromogranin A in human hypertension. Influence of heredity. Hypertension. 1995;26:213–20.

    PubMed  CAS  Google Scholar 

  • Ceconi C, Ferrari R, Bachetti T, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002;23:967–74.

    PubMed  CAS  Google Scholar 

  • Omland T, Dickstein K, Syversen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med. 2003;114:25–30.

    PubMed  CAS  Google Scholar 

  • Al-Shoumer KA, Vasanthy BA. Serum chromogranin A concentration in hyperthyroidism before and after medical treatment. J Clin Endocrinol Metab. 2009;94:2321–4.

    PubMed  CAS  Google Scholar 

  • Valeur J, Milde AM, Helle KB, Berstad A. Low serum chromogranin A in patients with self-reported food hypersensitivity. Scand J Gastroenterol. 2008;43:1403–4.

    PubMed  Google Scholar 

  • Bauer SH, Zhang XY, Van Dongen W, Claeys M, Przybylski M. Chromogranin A from bovine adrenal medulla: molecular characterization of glycosylations, phosphorylations, and sequence heterogeneities by mass spectrometry. Anal Biochem. 1999;274:69–80.

    PubMed  CAS  Google Scholar 

  • Verderio P, Dittadi R, Marubini E, et al. An Italian program of external quality control for chromogranin A (CgA) assay: performance evaluation of CgA determination. Clin Chem Lab Med. 2007;45:1244–50.

    PubMed  CAS  Google Scholar 

  • Woltering EA, Hilton RS, Zolfoghary CM, et al. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin A levels and symptom frequency. Pancreas. 2006;33:250–4.

    PubMed  CAS  Google Scholar 

  • Portel-Gomes GM, Grimelius L, Johansson H, Wilander E, Stridsberg M. Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. Am J Surg Pathol. 2001;25:1261–7.

    PubMed  CAS  Google Scholar 

  • Modlin IM, Kidd M, Pfragner R, Eick GN, Champaneria MC. The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab. 2006;91:2340–8.

    PubMed  CAS  Google Scholar 

  • Rindi G, Buffa R, Sessa F, Tortora O, Solcia E. Chromogranin A, B and C immunoreactivities of mammalian endocrine cells. Distribution, distinction from costored hormones/prohormones and relationship with the argyrophil component of secretory granules. Histochemistry. 1986;85:19–28.

    PubMed  CAS  Google Scholar 

  • Nikou GC, Marinou K, Thomakos P, et al. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology. 2008;8(4–5):510–9.

    PubMed  CAS  Google Scholar 

  • Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol. 2008;6:820–7.

    PubMed  CAS  Google Scholar 

  • Kölby L, Bernhardt P, Swärd C, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept. 2004;120(1–3):269–73.

    PubMed  Google Scholar 

  • Kimura N, Miura W, Noshiro T, et al. Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones. Endocr J. 1997;44:319–27.

    PubMed  CAS  Google Scholar 

  • Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut. 1998;43:223–8.

    Article  PubMed  CAS  Google Scholar 

  • Tomassetti P, Migliori M, Caletti GC, et al. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med. 2000;343:551–4.

    PubMed  CAS  Google Scholar 

  • Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther. 2000;14:557–60.

    PubMed  CAS  Google Scholar 

  • Kouraklis G, Misiakos E, Glinavou A, Raftopoulos J, Karatzas G. Management of enterochromaffin-like gastric carcinoid tumour metastasized to the liver. Scand J Gastroenterol. 2002;37:246–8.

    PubMed  CAS  Google Scholar 

  • Hellman P, Ladjevardi S, Skogseid B, Akerström G, Elvin A. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg. 2002;26:1052–6.

    PubMed  Google Scholar 

  • Abou-Saif A, Gibril F, Ojeaburu JV, et al. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer. 2003;98:249–61.

    PubMed  CAS  Google Scholar 

  • Fykse V, Sandvik AK, Qvigstad G, et al. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol. 2004;39:621–8.

    PubMed  CAS  Google Scholar 

  • Teunissen JJ, Kwekkeboom DJ, de Jong M, et al. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol. 2005;19:595–616.

    PubMed  CAS  Google Scholar 

  • Dakin GF, Warner RR, Pomp A, Salky B, Inabnet WB. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol. 2006;93:368–72.

    PubMed  Google Scholar 

  • Olausson M, Friman S, Herlenius G, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl. 2007;13:327–33.

    PubMed  Google Scholar 

  • Grozinsky-Glasberg S, Kaltsas G, Gur C, et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol. 2008;159:475–82.

    PubMed  CAS  Google Scholar 

  • Campana D, Nori F, Pezzilli R, et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer. 2008;15:337–42.

    PubMed  CAS  Google Scholar 

  • Korse CM, Bonfrer JM, Aaronson NK, Hart AA, Taal BG. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology. 2009;89:296–301.

    PubMed  CAS  Google Scholar 

  • Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311–8.

    PubMed  Google Scholar 

  • Korse CM, Taal BG, de Groot CA, Bakker RH, Bonfrer JM. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol. 2009;27:4293–9.

    PubMed  CAS  Google Scholar 

  • Kidd M, Modlin IM, Mane SM, Camp RL, Shapiro MD. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. Ann Surg. 2006;243:273–80.

    PubMed  Google Scholar 

  • Portela-Gomes GM, Stridsberg M. Selective processing of chromogranin A in the different islet cells in human pancreas. J Histochem Cytochem. 2001;49:483–90.

    PubMed  CAS  Google Scholar 

  • Portela-Gomes GM, Stridsberg M. Chromogranin A in the human gastrointestinal tract: an immunocytochemical study with region-specific antibodies. J Histochem Cytochem. 2002;50:1487–92.

    PubMed  CAS  Google Scholar 

  • Jirasek T, Hozak P, Mandys V. Different patterns of chromogranin A and Leu-7 (CD57) expression in gastrointestinal carcinoids: immunohistochemical and confocal laser scanning microscopy study. Neoplasma. 2003;50:1–7.

    PubMed  CAS  Google Scholar 

  • Qvigstad G, Sandvik AK, Brenna E, Aase S, Waldum HL. Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique. Histochem J. 2000;32:551–6.

    PubMed  CAS  Google Scholar 

  • Bofin AM, Qvigstad G, Waldum C, Waldum HL. Neuroendocrine differentiation in carcinoma of the breast. Tyramide signal amplification discloses chromogranin A–positive tumour cells in more breast tumours than previously realized. APMIS. 2002;110:658–64.

    PubMed  CAS  Google Scholar 

  • Fossmark R, Martinsen TC, Qvigstad G, et al. Ultrastructure and chromogranin A immunogold labelling of ECL cell carcinoids. APMIS. 2005;113(7–8):506–12.

    PubMed  Google Scholar 

  • Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16:885–94.

    PubMed  CAS  Google Scholar 

  • Klimstra DS, Modlin IR, Adsay NV, et al. Pathologic reporting of neuroendocrine tumors: application of the delphic consensus process to the development of a minimum pathologic data set. Am J Pathol. 2010;34:300–13.

    Google Scholar 

  • Feldman SA, Eiden LE. The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr Pathol. 2003;14:3–23.

    PubMed  CAS  Google Scholar 

  • Grossrubatscher E, Dalino P, Vignati F, et al. The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf). 2006;65:287–93.

    CAS  Google Scholar 

  • Peracchi M, Conte D, Gebbia C, et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol. 2003;148:39–43.

    PubMed  CAS  Google Scholar 

  • Nobels FR, Kwekkeboom DJ, Coopmans W, et al. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas. J Clin Endocrinol Metab. 1993;77:784–9.

    PubMed  CAS  Google Scholar 

  • Sciola V, Massironi S, Conte D, et al. Plasma chromogranin A in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:867–71.

    PubMed  Google Scholar 

  • Sidhu R, McAlindon ME, Leeds JS, Skilling J, Sanders DS. The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. J Gastrointestin Liver Dis. 2009;18:23–26.

    PubMed  Google Scholar 

  • Tsao KC, Wu TL, Chang PY, Hong JH, Wu JT. Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers. J Clin Lab Anal. 2006;20:42–6.

    PubMed  Google Scholar 

  • Wu JT, Erickson AJ, Tsao KC, Wu TL, Sun CF. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Ann Clin Lab Sci. 2000;30:175–8.

    PubMed  Google Scholar 

  • Capellino S, Lowin T, Angele P, et al. Increased chromogranin A levels indicate sympathetic hyperactivity in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2008;35:91–9.

    PubMed  CAS  Google Scholar 

  • di Comite G, Marinosci A, Di Matteo P, et al. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis. Ann N Y Acad Sci. 2006;1069:428–37.

    PubMed  CAS  Google Scholar 

  • Hirschowitz BI, Worthington J, Mohnen J, Haber M. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia. Aliment Pharmacol Ther. 2007;26:869–78.

    Article  PubMed  CAS  Google Scholar 

  • Kim BW, Lee BI, Kim HK, et al. [Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin]. Korean J Gastroenterol. 2009;53:84–9.

    PubMed  CAS  Google Scholar